Omega-3 Fatty Acids in the Prevention of Cardiovascular Diseases: Still Relevant?
DOI:
https://doi.org/10.12775/JEHS.2026.95.73658Keywords
omega-3 fatty acids, eicosapentaenoic acid, docosahexaenoic acid, cardiovascular prevention, hypertriglyceridaemia, REDUCE-IT, icosapentaenoic acid, polyunsaturated fatty acids, randomized controlled trials, lipid-lowering therapyAbstract
Background: Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, responsible for an estimated 17.9 million deaths annually. Omega-3 polyunsaturated fatty acids (PUFAs) - principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) derived from marine sources, and alpha-linolenic acid (ALA) from plant sources - have been investigated for decades as potential modulators of cardiovascular risk. Early epidemiological data from Greenlandic Inuit populations and subsequent prospective cohort studies generated substantial optimism regarding their cardioprotective potential. However, a series of large-scale randomized controlled trials conducted between 2018 and 2022 produced conflicting results, reigniting debate about the clinical utility of omega-3 supplementation.
References
1. Bang HO, Dyerberg J, Hjorne N. The composition of food consumed by Greenlandic Eskimos. Acta Med Scand. 1976;200(1-2):69–73.
2. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354(9177):447–455.
3. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–1098.
4. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapentaenoic acid for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.
5. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268–2280.
6. ORIGIN Trial Investigators. n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309–318.
7. ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540–1550.
8. Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380(1):23–32.
9. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;3(3):CD003177.
10. Gencer B, Djousse L, Al-Ramady OT, Cook NR, Manson JE, Albert CM. Effect of long-term marine omega-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation. 2021;144(25):1981–1990.
11. Bhatt DL, Miller M, Brinton EA, et al. REDUCE-IT USA: results from the 3146 patients randomized in the United States. Circulation. 2020;141(5):367–375.
12. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140(12):e673–e691.
13. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111–188.
14. Harris WS, Tintle NL, Imamura F, et al. Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies. Nat Commun. 2021;12(1):2329.
15. Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017;45(5):1105–1115.
16. Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution. Semin Immunol. 2015;27(3):200–215.
17. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378(25):e34.
18. Mason RP, Libby P, Bhatt DL. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. 2020;40(5):1135–1147.
19. Bhatt DL, Steg PG, Brinton EA, et al. Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapentaenoic acid-intervention trial. Clin Cardiol. 2017;40(3):138–148.
20. Miller PE, Van Elswyk M, Alexander DD. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens. 2014;27(7):885–896.
21. Kwak SM, Myung SK, Lee YJ, Seo HG. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172(9):686–694.
22. Roncaglioni MC, Tombesi M, Avanzini F, et al. n-3 Fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368(19):1800–1808.
23. Sala-Vila A, Guasch-Ferre M, Hu FB, et al. Dietary alpha-linolenic acid, marine omega-3 fatty acids, and mortality in a population with high fish consumption: findings from the PREvención con DIeta MEDiterránea (PREDIMED) study. J Am Heart Assoc. 2016;5(1):e002543.
24. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99(6):779–785.
25. Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2017;135(15):e867–e884.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Marcelina Rybińska, Hanna Rzepka, Paweł Stępowski, Mateusz Tajster
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 49
Number of citations: 0
